A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies

[1]  Y. Oji,et al.  Encouraging Clinical Evolution of a Pediatric Patient With Relapsed Diffuse Midline Glioma Who Underwent WT1-Targeting Immunotherapy: A Case Report and Literature Review , 2020, Frontiers in Oncology.

[2]  R. Rabadán,et al.  Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma , 2019, Nature Medicine.

[3]  J. Sakamoto,et al.  A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma , 2018, Cancer Immunology, Immunotherapy.

[4]  Man Xiao,et al.  Phase I/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer , 2018, Cancer Immunology, Immunotherapy.

[5]  David A Scheinberg,et al.  Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia. , 2018, Blood advances.

[6]  Yusuke Nakamura,et al.  WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia , 2018, Experimental Hematology & Oncology.

[7]  M. Zauderer,et al.  A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma , 2017, Clinical Cancer Research.

[8]  K. Hongo,et al.  Clinical effect and immunological response in patients with advanced malignant glioma treated with WT1-pulsed dendritic cell-based immunotherapy: A report of two cases , 2017 .

[9]  A. Rhodes,et al.  Expression of WT1 and PAX8 in the epithelial tumours of Malaysian women with ovarian cancer , 2017, British journal of biomedical science.

[10]  Benjamin M. Ellingson,et al.  Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials , 2017, Neurotherapeutics.

[11]  R. Colen,et al.  Cancer Imaging in Immunotherapy. , 2017, Advances in experimental medicine and biology.

[12]  S. Partlová,et al.  Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines , 2016, Oncotarget.

[13]  T. Yoshimine,et al.  Functional Roles of Wilms’ Tumor 1 (WT1) in Malignant Brain Tumors , 2016 .

[14]  A. Carella,et al.  Wilms’ Tumor Gene (WT1) Expression and Minimal Residual Disease in Acute Myeloid Leukemia , 2016 .

[15]  Naoya Hashimoto,et al.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.

[16]  K. Hongo,et al.  Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. , 2015, Journal of neurosurgery.

[17]  Jingting Jiang,et al.  Wilms’ tumor 1 enhances Cisplatin‐resistance of advanced NSCLC , 2014, FEBS letters.

[18]  T. Yoshimine,et al.  Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis. , 2014, Anticancer research.

[19]  J. Xu,et al.  WT1 Promotes Cell Proliferation in Non-Small Cell Lung Cancer Cell Lines through Up-Regulating Cyclin D1 and p-pRb In Vitro and In Vivo , 2013, PloS one.

[20]  Lorne A. Babiuk,et al.  Mechanisms of Action of Adjuvants , 2013, Front. Immunol..

[21]  S. Canevari,et al.  The value of PAX8 and WT1 molecules in ovarian cancer diagnosis. , 2013, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.

[22]  G. Soma,et al.  WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. , 2011, Anticancer research.

[23]  H. Ueno,et al.  Phase 1 Trial of Wilms Tumor 1 (WT1) Peptide Vaccine and Gemcitabine Combination Therapy in Patients With Advanced Pancreatic or Biliary Tract Cancer , 2011, Journal of immunotherapy.

[24]  H. Ueno,et al.  Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites. , 2010, Japanese journal of clinical oncology.

[25]  P. Greenberg,et al.  Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909 , 2010, Cancer Immunology, Immunotherapy.

[26]  H. Hollema,et al.  Potential Target Antigens for a Universal Vaccine in Epithelial Ovarian Cancer , 2010, Clinical & developmental immunology.

[27]  A. Magliocco,et al.  WT1 Immunoprofiling and Comparison of Malignant Mullerian Mixed Tumors of The Female Genital Tract , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[28]  J. Wolchok,et al.  Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. , 2010, Blood.

[29]  Y. Takeda,et al.  A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination. , 2010, Anticancer research.

[30]  J. Sakamoto,et al.  Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. , 2009, Anticancer research.

[31]  E. Thiel,et al.  A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. , 2009, Blood.

[32]  J. Hatazawa,et al.  Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. , 2008, Journal of neurosurgery.

[33]  Jeffrey S Barrett,et al.  Shortening the timeline of pediatric phase I trials: the rolling six design. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  K. Rezvani,et al.  Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. , 2007, Blood.

[35]  W. Broaddus,et al.  Wilms tumor 1 expression in malignant gliomas and correlation of +KTS isoforms with p53 status. , 2007, Journal of neurosurgery.

[36]  J. Inazawa,et al.  Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma , 2007, Virchows Archiv.

[37]  T. Shuin,et al.  WT1 (Wilms' Tumor 1) Peptide Immunotherapy for Renal Cell Carcinoma , 2007, Microbiology and immunology.

[38]  H. Lyerly,et al.  Immunotherapeutic targeting of Wilms' tumor protein. , 2007, Current opinion in molecular therapeutics.

[39]  J. Sakamoto,et al.  Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. , 2007, International journal of hematology.

[40]  J. Sakamoto,et al.  Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. , 2007, International journal of hematology.

[41]  E. Thiel,et al.  Vaccination with the WT-1 126-134 Peptide in Patients with Acute Myeloid Leukemia after Allogenic Stem Cell Transplantation. , 2006 .

[42]  I. Kawase,et al.  Immunohistochemical detection of WT1 protein in a variety of cancer cells , 2006, Modern Pathology.

[43]  A. Geater,et al.  WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study , 2006, BMC Cancer.

[44]  J. Hatazawa,et al.  A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. , 2006, Japanese journal of clinical oncology.

[45]  Kunle Odunsi,et al.  Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. , 2006, Gynecologic Oncology.

[46]  K. Tabuchi,et al.  Expression of the Wilms' tumor gene product WT1 in glioblastomas and medulloblastomas , 2006, Brain Tumor Pathology.

[47]  H. Sugiyama.  Cancer immunotherapy targeting Wilms’ tumor gene WT1 product , 2005, Expert review of vaccines.

[48]  M. Waldstrøm,et al.  Immunohistochemical expression of wilms tumor gene protein in different histologic subtypes of ovarian carcinomas. , 2005, Archives of pathology & laboratory medicine.

[49]  T. Kyo,et al.  Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[50]  A. Gown,et al.  Wilms Tumor Gene Product: Sensitive and Contextually Specific Marker of Serous Carcinomas of Ovarian Surface Epithelial Origin , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[51]  Yoshifumi Yamamoto,et al.  Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma , 2003, Cancer Science.

[52]  D Middleton,et al.  New allele frequency database: http://www.allelefrequencies.net. , 2003, Tissue antigens.

[53]  S. Miyoshi,et al.  Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers , 2002, International journal of cancer.

[54]  E. Bertelmann,et al.  Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens , 2000, Journal of Cancer Research and Clinical Oncology.